KQB-198(KQB-198) - 在研适应症：慢性期费城染色体阳性慢性粒细胞白血病，晚期恶性实体瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

KQB-198

靶点-

作用方式-

作用机制-

治疗领域

肿瘤血液及淋巴系统疾病

在研适应症

慢性期费城染色体阳性慢性粒细胞白血病晚期恶性实体瘤

非在研适应症-

原研机构

Kumquat Biosciences, Inc.初创企业

在研机构

Kumquat Biosciences, Inc.初创企业

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 KQB-198 相关的临床试验

NCT06645886

/ Recruiting临床1期

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies

The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:
* What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?
* Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?
* What happens to KQB198 in the body?
Participants will:
* Take KQB198 daily, alone or in combination with another anti-cancer drug
* Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

开始日期2024-12-09

申办/合作机构

Kumquat Biosciences, Inc.初创企业

CTIS2024-511453-22-00

/ Recruiting临床1期

- KQB198-101

开始日期2024-11-29

申办/合作机构

Kumquat Biosciences, Inc.初创企业

NCT06507306

/ Recruiting临床1期

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB198 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:
* What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?
* Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?
* What happens to KQB198 in the body?
Participants will:
* Take KQB198 daily, alone or in combination with another anti-cancer drug
* Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

开始日期2024-06-03

申办/合作机构

Kumquat Biosciences, Inc.初创企业

100 项与 KQB-198 相关的临床结果

登录后查看更多信息

100 项与 KQB-198 相关的转化医学

登录后查看更多信息

100 项与 KQB-198 相关的专利（医药）

登录后查看更多信息

100 项与 KQB-198 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	美国	Kumquat Biosciences, Inc.初创企业	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	法国	Kumquat Biosciences, Inc.初创企业	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	意大利	Kumquat Biosciences, Inc.初创企业	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	波兰	Kumquat Biosciences, Inc.初创企业	2024-12-09
慢性期费城染色体阳性慢性粒细胞白血病	临床1期	西班牙	Kumquat Biosciences, Inc.初创企业	2024-12-09
晚期恶性实体瘤	临床1期	美国	Kumquat Biosciences, Inc.初创企业	2024-06-03
晚期恶性实体瘤	临床1期	法国	Kumquat Biosciences, Inc.初创企业	2024-06-03
晚期恶性实体瘤	临床1期	意大利	Kumquat Biosciences, Inc.初创企业	2024-06-03
晚期恶性实体瘤	临床1期	西班牙	Kumquat Biosciences, Inc.初创企业	2024-06-03
晚期恶性实体瘤	临床1期	中国台湾	Kumquat Biosciences, Inc.初创企业	2024-06-03